UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~October 331, 2025

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41141	98-0668934
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

301 Rte. 17 North, Ste. 800, Rutherford, NJ		07070
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GCTK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7 5.0107. ~~Regulation~~Submission FDof ~~Disclosure~~Matters to a Vote of Security Holders.

On ~~November~~October 331, 2025 at 12:00 p.m. Eastern Time, Glucotrack, Inc., ~~a Delaware corporation~~ (the “Company”), ~~issued~~convened aand ~~press~~then ~~release~~adjourned its special meeting of the stockholders (the “~~Press Release~~Meeting”). The ~~Press~~only ~~Release~~proposal issubmitted ~~furnished~~for ~~herewith~~a asvote ~~Exhibit~~of 99the stockholders at the Meeting was the approval of the adjournment of such meeting (the “Adjournment Proposal”).1.

~~The~~As ~~information~~of inthe ~~this~~close ~~Item~~of ~~7.01~~business, ~~including~~on ~~Exhibit~~September ~~99.1~~23, ~~shall~~2025, ~~not~~the berecord ~~deemed~~date ~~“filed”~~ for ~~purposes of Section 18 of~~ the ~~Securities Exchange Act of 1934~~Meeting, asthere ~~amended~~were ~~(the “Exchange Act”)~~899,410 orshares ~~otherwise subject to the liabilities~~ of ~~that~~common ~~section,~~stock ~~unless the~~outstanding ~~Company~~and ~~specifically~~entitled ~~states~~to ~~that~~vote, ~~the~~16.4% ~~information~~of iswhich toshares bewere ~~considered~~represented ~~“filed”~~in ~~under~~person ~~the Exchange Act~~ or ~~specifically incorporates it~~ by ~~reference~~proxy ~~into~~at ~~a filing under~~ the ~~Securities~~Meeting, ~~Act~~which ofdid ~~1933,~~not asconstitute ~~amended,~~a orquorum to ~~the~~conduct ~~Exchange Act~~business.

~~Item~~As ~~9.01~~described ~~Financial~~in ~~Statements~~detail in the definitive proxy statement (the “Proxy Statement”) related to the Meeting filed by the Company with the Securities and ~~Exhibits~~Exchange Commission on October 3, 2025, the Adjournment Proposal was presented to stockholders at the Meeting to seek their approval to adjourn the Meeting to another time to solicit additional proxies to obtain sufficient votes to constitute a quorum.

~~(d)~~The ~~Exhibits~~following is a tabulation of the votes with respect to the Adjournment Proposal, which was approved by the Company’s stockholders:

Exhibit No.		Description
99.1		Press Release dated November 3, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

Approval of the Adjournment Proposal

Votes For				Votes Against				Abstain/Withhold
	136,928				8,655				1,923

The Meeting has been adjourned to November 7, 2025 at 12:00 p.m. Eastern Time (the “Adjourned Meeting”). You are permitted to attend the Adjourned Meeting online at https://www.virtualshareholdermeeting.com/GCTK2025M2.

At the Adjourned Meeting, stockholders will be asked to vote on the Issuance Proposal, as described in detail in the Proxy Statement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2025
Date: November 6, 2025
	GLUCOTRACK, INC.
	By:	/s/ Paul Goode
	Name:	Paul Goode
	Title:	Chief Executive Officer

Filing Compare · Glucotrack, Inc.